Antibody Information
General Information of This Antibody
| Antibody ID | ANI0BOAGM |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Trastuzumab variant |
|||||
| Organization | Alteogen, Inc.; Shenyang Sunshine Pharmaceutical Co., Ltd. |
|||||
| Synonyms |
Trastuzumab variant
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antigen Name | Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
HM2- MMAE [Phase 1 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
13.3% (4.2 mg/kg)
|
|||
| Patients Enrolled |
Patients with HER2-positive advanced breast cancer progressive to at least two kinds of prior anti-HER2 treatment.
|
||||
| Administration Dosage |
0.30-4.80 mg/kg iv administered once every 3 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03281824 | Clinical Status | Phase 1 | ||
| Clinical Description |
Open-label, dose increase and phase 1 study of ALT-P7 to determine safety, tolerability, pharmacokinetics for HER2 positive metastatic breast cancer patients who have progressed on previous trastuzumab-based therapy.
|
||||
References